Salivary concentrations of macrophage activation-related chemokines are influenced by non-surgical periodontal treatment

a 12-week follow-up study

Grande, Maria A.; Belstrøm, Daniel; Damgaard, Christian; Holmstrup, Palle; Könönen, Eija; Gursoy, Mervi; Gursoy, Ulvi Kahraman

Published in:
Journal of Oral Microbiology

DOI:
10.1080/20002297.2019.1694383

Publication date:
2020

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Grande, M. A., Belstrøm, D., Damgaard, C., Holmstrup, P., Könönen, E., Gursoy, M., & Gursoy, U. K. (2020). Salivary concentrations of macrophage activation-related chemokines are influenced by non-surgical periodontal treatment: a 12-week follow-up study. Journal of Oral Microbiology, 12(1), [1694383]. https://doi.org/10.1080/20002297.2019.1694383
Salivary concentrations of macrophage activation-related chemokines are influenced by non-surgical periodontal treatment: a 12-week follow-up study

Maria A. Grande, Daniel Belstrøm, Christian Damgaard, Palle Holmstrup, Eija Könönen, Mervi Gursoy & Ulvi Kahraman Gursoy

To cite this article: Maria A. Grande, Daniel Belstrøm, Christian Damgaard, Palle Holmstrup, Eija Könönen, Mervi Gursoy & Ulvi Kahraman Gursoy (2020) Salivary concentrations of macrophage activation-related chemokines are influenced by non-surgical periodontal treatment: a 12-week follow-up study, Journal of Oral Microbiology, 12:1, 1694383, DOI: 10.1080/20002297.2019.1694383

To link to this article: https://doi.org/10.1080/20002297.2019.1694383

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 09 Dec 2019.

Submit your article to this journal

Article views: 353

View related articles

View Crossmark data
Salivary concentrations of macrophage activation-related chemokines are influenced by non-surgical periodontal treatment: a 12-week follow-up study

Maria A. Grande, Daniel Belström, Christian Damgaard, Palle Holmstrup, Eija Könönen, Mervi Gursoy and Ulvi Kahraman Gursoy

**Section for Periodontology, Microbiology and Community Dentistry, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; **Department of Cancer and Inflammation, Institute of Molecular Medicine, Faculty of Health and Medical Sciences, University of Southern Denmark, Odense, Denmark; **Department of Periodontology, Institute of Dentistry, University of Turku, Turku, Finland

**ABSTRACT**

**Background:** During periodontal inflammation, bacteria induces chemokine expression and migration of various inflammatory cells. The aim of the study was to learn if periodontal treatment alters salivary concentrations of macrophage activation-related chemokines and if such alterations correlate with abundance of periodontitis-associated bacteria.

**Methods:** Twenty-five patients with periodontitis completed the study (NCT02913248 at clinicaltrials.gov). Periodontal parameters and stimulated saliva samples were obtained at baseline and 2, 6 and 12 weeks after non-surgical periodontal treatment. Salivary concentrations of monocyte chemoattractant proteins (MCP-1-4), macrophage-derived chemokine (MDC), macrophage migration inhibitory factor (MIF), monokine induced by interferon-gamma (MIG), macrophage inflammatory protein (MIP-1α) and interferon-inducible protein (IP-10) were quantified using the LumineX™ xMAP™ technique and abundance of bacteria was quantified using next-generation sequencing.

**Results:** The treatment improved all periodontal parameters and caused an increase in the concentrations of MCP-2, MDC and MIP-1α at week 12 compared to baseline, week 2 and week 6, respectively. Salivary concentrations of MCP-1-2, MDC, MIG, MIP-1α and IP-10 correlated with the abundance of specific periodontitis-associated bacteria.

**Conclusions:** Periodontal treatment impacts salivary concentrations of MCP-2, MDC and MIP-1α, which correlate with the abundance of specific periodontitis-associated bacteria. This indicates that these chemokines reflect periodontal status and possess potential in illustrating a response to treatment.

**Introduction**

Chemokines are referred to as ‘chemotactic cytokines’ as they activate and promote migration of a variety of inflammatory cells by dictating the type and magnitude of immune response [1]. A persistent production of chemokines and recruitment of leukocytes characterizes chronic inflammation such as periodontitis [2,3].

Periodontitis is a multifactorial inflammatory disease affecting up to 50% of the adult population in the Western world [4]. Etiologically, a polymicrobial biofilm initiates and maintains a destructive inflammatory response in the tooth-supporting tissues. Specifically, subgingival presence of the red complex bacteria *Porphyromonas gingivalis*, *Treponema denticola* and *Tannarella forsythia* strongly associate with periodontitis [5]. Lipopolysaccharide (LPS), a biologically active structure on the Gram-negative bacteria, can be recognized by pattern recognition receptors (PRRs) and activate resident cells to produce several chemokines, e.g. interleukin (IL) –8 (CXCL8), monocyte chemoattractant proteins (MCPs), macrophage inflammatory protein (MIP)-1α and interferon-inducible protein (IP)-10 [6]. Increased concentrations of MCP-1, MCP-3, macrophage migration inhibitory factor (MIF), MIP-1α, IP-10 and macrophages have been demonstrated in inflamed gingival biopsies, as compared to biopsies from healthy gingival sites [7–11]. Moreover, increased concentrations of chemokines like MIP-1α in saliva have been reported to associate with periodontitis [12–16]. This suggests that concentrations of chemokines in saliva can reflect local periodontal inflammation.

Cross-sectional studies have demonstrated an increase in salivary concentrations of both microbial- and host-inflammatory biomarkers in patients with periodontitis [14,17–20]. However, longitudinal studies, which test saliva’s ability to reflect periodontal inflammation are limited [16,21–23]. In a recently performed longitudinal study, we found, that saliva...
reflects subgingival abundance of specific bacteria associated with periodontitis; *P. gingivalis, T. denticola, T. forsythia, Prevotella intermedia, Parvimonas micra and Filifactor alocis* before and after non-surgical periodontal treatment [24]. The aim of the present study was, therefore, to use the same salivary samples to learn if periodontal treatment influences the macrophage activation-related chemokine concentrations in saliva. We tested the hypotheses that non-surgical periodontal treatment has impact on salivary concentrations of the chemokines; MCP-1(CCL2), MCP-2(CCL8), MCP-3(CCL7), MCP-4(CCL13), macrophage-derived chemokine (MDC or CCL22), MIF, monokine induced by interferon-gamma (MIG or CXCL9), MIP-1α and IP-10 (CXCL10). Thereto, that changes in salivary chemokine concentrations will correlate with salivary abundance of *P. gingivalis, T. denticola, T. forsythia, P. intermedia, P. micra and F. alocis*.

**Materials and methods**

**Study population**

This study is part of a series of studies of a population, which has previously been described in detail [24]. Briefly, 31 patients with moderate to severe generalized periodontitis, as defined by the American Academy of Periodontology [25], were enrolled in the study. All patients approved their study participation by signing a written informed consent before commencement. Inclusion criteria: Age ≥ 40 yrs., teeth ≥ 20, Caucasian. Exclusion criteria: Treatment involving caries, hyposalivation, systemic diseases, current use of medication with known effect on the periodontium, professional dental cleaning or/and antibiotic treatment within the last 3 months. The study was accepted by the regional ethical committee of the capital region of Denmark (H-16,016,368), reported to the Danish Data Authority (SUND-2016-58) and registered at clinicaltrials.gov (NCT02913248).

**Clinical examination and periodontal treatment**

The study was performed from September 2016 to the beginning of January 2017 at the Department of Odontology, University of Copenhagen. Non-surgical periodontal treatment was performed at baseline. The treatment consisted of comprehensive individual hygiene instructions followed by scaling and root planing. Full-mouth periodontal recordings (third molars excluded) were obtained at baseline and 12 weeks after therapy. The periodontal recordings were measured at six sites per tooth and included registrations of plaque index (PI), bleeding on probing (BOP), probing pocket depth (PD) and clinical attachment level (CAL). Control visits were performed 2 and 6 weeks after treatment. PI and BOP were recorded, and oral hygiene instructions were repeated, if plaque was present upon application of erythrosine. All recordings and treatments were performed by the same clinician (MAG).

**Saliva sampling**

Stimulated saliva samples were collected at baseline and 2, 6 and 12 weeks after the non-surgical periodontal treatment. Samples were collected from 8 am to 3 pm by the same clinician (MAG). Sampling was performed from each patient at each visit within a time-interval of 4 h. Before sampling, the participants flushed their mouth with tap water, and thereafter paraffin-stimulated whole saliva was collected to a minimum of 2 mL. All samples were immediately frozen, then stored at −80°C until further analysis at the University of Turku laboratories.

**Analysis of salivary chemokines**

Saliva samples were thawed and centrifuged at 9300 g for 5 min at room temperature. MCP-1, MCP-2, MCP-3, MCP-4, macrophage-derived chemokine (MDC), MIF, monokine induced by IFN-gamma (MIG), MIP-1α and IP-10 were identified in supernatants using the Luminex xMAP technic (Luminex Corporation, Austin, TX) with optimized commercial kits (Pro-human cytokine group 1 assays; Bio-Rad, Santa Rosa, CA), according to the manufacturers’ protocol.

The limit of detection (LOD) for the assay, i.e. the minimum concentration of an analyte where the fluorescence intensity signal could be detected, was 0.1 pg/ml for MCP-1, 0.04 pg/ml for MCP-2, 1.3 pg/ml for MCP-3, 0.1 pg/ml for MCP-4, 0.5 pg/ml for MDC, 15.4 pg/ml for MIF, 1.1 pg/ml for MIG, 0.3 pg/ml for MIP-1α and 1.1 pg/mg for IP-10.

**Analysis of bacteria**

DNA isolation and next-generation sequencing were performed as previously described in detail [24]. In brief, bacterial DNA was isolated using MagNA Pure 96 instrument (Roche, Mannheim, Germany). Next-generation sequencing of the V3-V4 region of the 16S rDNA gene was performed using the Human Oral Microbe Identification Using Next Generation Sequencing (HOMINGS) technique. Sequences were blasted against reference sequences in Probeseq, which contains 692 reference sequences based on the HOMD database [26].

**Statistics**

All data were checked for normal distribution with box-plot- and histogram-illustrations. Repeated t-test
was used to compare the clinical data (PI, BOP, PD, CAL). Friedman’s test was used to analyze changes in chemokine concentrations (p < 0.01). When significant alterations were observed Wilcoxon signed-rank test with Bonferroni correction was used as post hoc analysis. By applying the Bonferroni correction, a p-value <0.008 was computed and considered as statistically significant. Correlations of chemokine concentrations with other chemokines and abundance of specific bacteria associated with periodontitis were tested using Spearman’s signed-rank test (p < 0.05). All statistical analyses were performed in Graph Pad Prism v8 (Graph Pad Software, San Diego, California).

Results
The study was completed by 25 patients [24]. One tube of saliva broke during centrifugation, which resulted in exclusion of all samples from this patient. The chemokine concentrations from the remaining 24 patients were above the detection limit of the test kit, except for MCP-3 concentrations in 10 samples and MCP-2 concentrations in one sample. The MCP-2 and MCP-3 concentrations below the LOD value were substituted with LOD/2 for the statistical analyses [27,28].

Non-surgical periodontal treatment improved all clinical parameters
The outcome of the clinical parameters has previously been published in detail [24]. In summary, non-surgical periodontal treatment resulted in significant improvements of PI, BOP, PD and CAL throughout the study period (p < 0.001). PI: 84.2% (baseline), 41% (week 2), 43% (week 6), 41.8% (week 12). BOP: 56% (baseline), 27.1% (week 2), 34.6% (week 6), 41.3% (week 12). PD: 3.4 mm (baseline), 3.0 mm (week 12). CAL: 4.1 mm (baseline), 3.7 mm (week 12).

Effect of non-surgical periodontal treatment on salivary chemokine concentrations
Alterations in salivary chemokine concentrations are illustrated in Figure 1. Non-surgical periodontal treatment significantly influenced the median salivary concentrations of MCP-2, MDC, MIG and MIP-1α (p < 0.01). A significant increase in concentrations of MCP-2, MDC and MIP-1α was observed at week 12 compared to baseline, week 2 and 6 (p < 0.008). The salivary concentrations of MCP-1, MCP-3, MCP-4, MIF, and IP-10 did not change significantly during the 12 weeks.

Correlations of chemokine concentrations
Correlations of salivary chemokine concentrations measured at baseline with concentrations recorded after 2, 6 and 12 weeks are illustrated in Table 1. Significant correlations of the baseline concentrations with those recorded at week 2 were observed for all nine chemokines tested (p < 0.05). At week 6, the concentrations of six chemokines still correlated significantly with baseline concentrations (p < 0.01). However, at week 12 only MCP-1 and MIG concentrations correlated with the baseline values (p < 0.05).

When correlations of different chemokine concentrations throughout the study period were tested, significant correlations were observed in selected chemokine groups; MCP-2/MCP-3/MCP-4, MDC/MIG/MIP-1α and MCP-1/MIP-1α/MIG/IP-10 (p < 0.001) (Table 2).

Correlations of salivary chemokine concentrations with abundance of bacteria associated with periodontitis in saliva
Relative abundance of bacteria associated with periodontitis in the saliva samples is previously described [24]. Correlations of salivary abundance of P. gingivalis, T. denticola, T. forsythia, P. intermedia, P. micra and F. alocis with salivary chemokine concentrations were tested, and data are presented in Table 3. Relative abundance of P. gingivalis correlated significantly with MCP-1, MDC and MIP-1α. Correlations of T. denticola with MCP-1-2, MIG and IP-10 were also observed. P. intermedia correlated with MCP-1 and MIG, F. alocis with MCP and MIP-1α and P. micra with IP-10. No correlations of the abundance of F. alocis with salivary concentrations of chemokines existed. (p < 0.05)

Discussion
The main finding of the present study was that non-surgical periodontal treatment affects salivary concentrations of MCP-2, MDC, MIG and MIP-1α (Figure 1). Moreover, the observed correlations between tested chemokine indicate that the expression and secretion pathways of these chemokines are inter-related (Table 2). To the best of our knowledge, this study is the first to analyze salivary concentrations of MCP-2, −4, MDC, MIG and IP-10 in periodontitis patients with a longitudinal design.

In general, the effect of non-surgical periodontal treatment on salivary concentrations of macrophage activation-related chemokines has only been tested in a limited number of studies [16,21]. In line with data from the present study, steady salivary MIP-1α concentrations have been reported in samples collected at baseline and 16 weeks after periodontal therapy [21].
In contrast, significant decreases in MCP-1 concentrations in saliva, gingival crevicular fluid (GCF), and serum have been observed 6 weeks after periodontal treatment [16]. An explanation for the different findings might be the variation in collection methods; stimulated versus unstimulated saliva, alternatively by the different use of analytical assays; Luminex versus ELISA. In the present study, chemokine concentrations were not significantly decreased as a consequence of non-surgical periodontal treatment. However, when comparing baseline concentrations with week 2 chemokine concentrations, a decrease of 32% was observed in MCP-1 concentrations, 11% in MIP-1α concentrations and 26.5% in MDC concentrations (Figure 1). The lack of statistical significance, despite the relatively big decreases observed, may be explained by the wide-range differences in inter-individual chemokine concentrations. Though a significant and steady increase in salivary concentrations of MCP-2, MDC, MIG and MIP-1α were noted from week 2 to week 12, which presumably reflects the gradual increase in local inflammation (BOP) starting in week 2 (Figure 1).

A significant correlation in baseline and week 2 concentrations for all nine chemokines was recorded. Interestingly, the number of correlating chemokines slowly decreased from week 2 until week 12 (Table 1). These results may indicate that also at the individual level the salivary chemokine concentrations were stable during the first 2 to 6 weeks after periodontal therapy. When the correlations of the different chemokine concentrations were analyzed, interactions in some chemokine groups, e.g. MCP-2/MCP-3/MCP-4, MDC/MIG/MIP-1α and MCP-1/MIP-1α/MIG/IP-10 (Table 2), were demonstrated. Various macrophage

Table 1. Correlation coefficients (R) of salivary concentrations of chemokines at baseline with concentrations recorded at week 2, week 6 and week 12. * (p < 0.05), ** (p < 0.01), *** (p < 0.001).

| Chemokine | Baseline vs week 2 | Baseline vs week 6 | Baseline vs week 12 |
|-----------|--------------------|--------------------|---------------------|
| MCP-1     | 0.81***            | 0.67**             | 0.65**              |
| MCP-2     | 0.58**             | 0.67**             | 0.22                |
| MCP-3     | 0.55*              | 0.51               | −0.24               |
| MCP-4     | 0.50*              | 0.40               | 0.075               |
| MDC       | 0.79***            | 0.36               | 0.36                |
| MIF       | 0.66**             | 0.53**             | 0.24                |
| MIG       | 0.64**             | 0.54**             | 0.41*               |
| MIP-1α    | 0.79***            | 0.62**             | 0.39                |
| IP-10     | 0.67**             | 0.76***            | 0.29                |

Figure 1. Scatter dot-plot of salivary concentrations of chemokines measured at baseline, week 2, week 6, and week 12. Horizontal-lines: Median-values. The black bars illustrate significant alterations using the Wilcoxon signed-rank tests with Bonferroni correction (p < 0.008). The faded lines (MIG) illustrate significant alterations, though with a higher P-value than decided by the Bonferroni correction (p < 0.05).
Correlation coefficients (R) of salivary concentrations of chemokines with the salivary relative abundance of six bacteria

| Chemokine | M. P. gingivalis | T. denticola | P. intermedia | F. alocis | T. forsythia | P. micra | Total bacterial burden |
|-----------|-----------------|-------------|---------------|-----------|--------------|---------|-----------------------|
| MCP-1     | 0.21*           | 0.24*       | 0.28**        | 0.20      | 0.18         | -0.08   | 0.30**                |
| MCP-2     | 0.09            | 0.25*       | 0.14          | 0.04      | -0.01        | 0.15    | 0.15                  |
| MCP-3     | 0.15            | 0.16        | -0.08         | -0.01     | 0.05         | 0.16    | 0.08                  |
| MCP-4     | 0.19            | 0.12        | -0.15         | 0.03      | 0.14         | 0.20    | 0.12                  |
| MDC       | 0.28**          | 0.10        | 0.01          | 0.22*     | 0.03         | -0.06   | 0.11                  |
| MIF       | 0.05            | 0.19        | 0.18          | 0.11      | 0.14         | -0.00   | 0.24*                 |
| MIG       | 0.09            | 0.21*       | 0.27**        | 0.16      | 0.01         | -0.18   | 0.09                  |
| MIP-1α     | 0.22*           | 0.08        | 0.13          | 0.36**    | 0.12         | 0.02    | 0.21*                 |
| IP-10      | 0.09            | 0.24*       | 0.08          | 0.11      | 0.12         | -0.27** | 0.11                  |

Table 3. Correlation coefficients (R) of salivary concentrations of chemokines with the salivary relative abundance of six bacteria associated with periodontitis and with the total bacterial burden. The total bacterial burden: The sum of the relative abundance of P. gingivalis, T. denticola, P. intermedia, F. alocis, T. forsythia and P. micra. *(p < 0.05), **(p < 0.01).**

Activation-related chemokines share receptors on target cells and activate the same pathways [29]. This information might explain the correlations of MCP-2/MCP-3 and MCP-4, as they all activate receptor CCR2, and the correlations of MIG and IP-10, as they activate receptor CXCR3. Finally, chemokine production can be induced by different inflammatory cytokines, which may also explain diversities in the expression and secretion of each chemokine [3]. In agreement with our findings, significant correlations of MCP-1, MIG and IP-10 have previously been shown during inflammation [30]. This may indicate that the salivary chemokine concentrations are prone to the interactions between various cytokines and chemokines.

Production of chemokines can be induced by bacteria. This is why significant associations between abundance of bacteria associated with periodontitis and concentrations of chemokines in inflamed tissue samples have been demonstrated [31]. Furthermore, it has been documented that stimulation of inflammatory cells with either P. gingivalis or bacterial LPS can cause an increase in the release of both MCP-1 and MIP-1α [2,32–34]. In line, we demonstrated a positive correlation in abundance of P. gingivalis with MCP-1 concentrations in saliva (Table 3). Novel findings in the present study are the correlations in abundance of F. alocis and P. micra with salivary concentrations of MDC, MIP-1α and IP-10 (Table 3). Inflammatory pathway activation depends on the activated PRR. F. alocis activates nucleotide-binding oligomerization domain-containing protein 1 (NOD1) and P. micra nucleotide-binding oligomerization domain-containing 2 (NOD2) [35]. The binding to different PRRs suggests species-dependent inflammatory pathways, which may explain the variations in correlations of chemokine concentrations and bacterial abundance observed. However, the exact contribution of these bacteria, associated with periodontitis, in the inflammatory cascades remains unexplained and requires further studies.

Some limitations apply to the present study. For example, airborne diseases and antibiotic treatment caused a drop-out of six patients, which resulted in a smaller sample size than estimated by the power calculation. Furthermore, analyses of chemokines in serum and site-specific samples (GCF or gingival biopsies) from diseased sites would have improved the understanding of the observed changes in salivary chemokine concentrations. The present use of stimulated saliva samples is a fast and easy alternative to unstimulated saliva samples, which minimizes the intra-individual variations in salivary flow rates [36]. Notably, available literature on the analyses of the salivary proteome in stimulated and unstimulated saliva samples possess conflicting results [37,38]. However, when examining the salivary microbiota comparable data have been reported in stimulated and unstimulated saliva samples [39]. Finally, it would have been interesting to include other inflammatory biomarkers such as complement proteins, as other parts of the immune system, together with chemokines, interact in the pro-inflammatory processes, and may improve the biomarker-related diagnostic potential in periodontitis patients [40].

In conclusion, treatment of periodontitis seems to influence the salivary concentrations of specific macrophage activation-related chemokines. Concentrations
of these chemokines correlate with salivary abundance of particular bacteria associated with periodontitis. This indicates that chemokines in saliva reflect periodontal status and possess potential as biomarkers illustrating response to treatment.

Data availability statement
Access to data will be provided upon request (mgra@sund.ku.dk).

Disclosure statement
The authors declare no conflict of interest in performing the study. All authors acknowledge their collaborators, at Forsyth Institute, Boston, Massachusetts, for processing the microbial analyses.

Funding
The Danish Foundation for Mutual Efforts in Dental Care supported this study.

ORCID
Christian Damgaard http://orcid.org/0000-0003-2394-746X

References
[1] White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation–therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65(1):47–89.
[2] Ryu OH, Choi Sj, Linares AMG, et al. Gingival epithelial cell expression of macrophage inflammatory protein-1alpha induced by interleukin-1beta and lipopolysaccharide. J Periodontol. 2007;78(8):1627–1634.
[3] Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 1997;349(9050):490–495.
[4] Eke PI, Thornton-Evans GO, Wei L, et al. Periodontitis in US adults: national health and nutrition examination survey 2009–2014. J Am Dent Assoc. 2018;149(7):576–886.
[5] Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000. 2005;38:135–187.
[6] Parisi L, Gini E, Baci D, et al. Macrophage polarization in chronic inflammatory diseases: killers or builders? J Immunol Res. 2018;2018:8791804.
[7] Garlet GP, Martins W Jr., Ferreira BR, et al. Patterns of chemokines and chemokine receptors expression in different forms of human periodontal disease. J Periodontal Res. 2003;38(2):210–217.
[8] Kabashima H, Yoneda M, Nagata K, et al. The presence of chemokine (MCP-1, MIP-1alpha, MIP-1beta, IP-10, RANTES)-positive cells and chemokine receptor (CCR5, CXCR3)-positive cells in inflamed human gingival tissues. Cytokine. 2002;20(2):70–77.
[9] Gemmell E, Carter CL, Seymour GJ. Chemokines in human periodontal disease tissues. Clin Exp Immunol. 2001;125(1):134–141.
[10] Dezerega A, Pozo P, Hernandez M, et al. Chemokine monocyte chemoattractant protein-3 in progressive periodontal lesions in patients with chronic periodontitis. J Periodontol. 2010;81(2):267–276.
[11] Garaicoa-Pazmino C, Fretwurst T, Squirize CH, et al. Characterization of macrophage polarization in periodontal disease. J Clin Periodontol. 2019;46:830–839.
[12] Fine DH, Markowitz K, Furgang D, et al. Macrophage inflammatory protein-1alpha: a salivary biomarker of bone loss in a longitudinal cohort study of children at risk for aggressive periodontal disease? J Periodontol. 2009;80(1):106–113.
[13] Nisha KJ, Suresh A, Anilkumar A, et al. MIP-1alpha and MCP-1 as salivary biomarkers in periodontal disease. Saudi Dent J. 2018;30(4):292–298.
[14] Ebersole JL, Nagarajan R, Akers D, et al. Targeted salivary biomarkers for discrimination of periodontal health and disease(s). Front Cell Infect Microbiol. 2015;5:62.
[15] Al-Sabbagh M, Alladah A, Lin Y, et al. Bone remodeling-associated salivary biomarker MIP-1alpha distinguishes periodontal disease. J Periodontal Res. 2012;47(3):389–395.
[16] Gupta M, Chaturvedi R, Jain A. Role of monocyte chemoattractant protein-1 (MCP-1) as an immune-diagnostic biomarker in the pathogenesis of chronic periodontal disease. Cytokine. 2013;61(3):892–897.
[17] Belstrom D, Fiehn NE, Nielsen CH, et al. Differences in bacterial saliva protein profile between periodontitis patients and a control cohort. J Clin Periodontol. 2014;41(2):104–112.
[18] Belstrom D, Paster BJ, Fiehn NE, et al. Salivary bacterial fingerprints of established oral disease revealed by the human oral microbe identification using next generation sequencing (HOMINGS) technique. J Oral Microbiol. 2016;8:30170.
[19] Gursoy UK, Kononen E, Pussinen PJ, et al. Use of host- and bacteria-derived salivary markers in detection of periodontitis: a cumulative approach. Dis Markers. 2011;30(6):299–305.
[20] Gursoy UK, Pussinen PJ, Salomaa V, et al. Cumulative use of salivary markers with an adaptive design improves detection of periodontal disease over fixed biomarker thresholds. Acta Odontol Scand. 2018;76(7):493–496.
[21] Sexton WM, Lin Y, Kryscio RJ, et al. Salivary biomarkers of periodontal disease in response to treatment. J Clin Periodontol. 2011;38(5):434–441.
[22] Kinney JS, Morelli T, Braun T, et al. Saliva/pathogen biomarker signatures and periodontal disease progression. J Dent Res. 2011;90(6):752–758.
[23] Fine DH, Markowitz K, Fairlie K, et al. Macrophage inflammatory protein-1 alpha shows predictive value as a risk marker for subjects and sites vulnerable to bone loss in a longitudinal model of aggressive periodontitis. PloS One. 2014;9(6):e89541.
[24] Belstrom D, Grande MA, Sembler-Moller ML, et al. Influence of periodontal treatment on subgingival and salivary microbiotas. J Periodontol. 2018;89(5):531–539.
[25] American academy of periodontology task force report on the update to the 1999 classification of periodontal diseases and conditions. J Periodontol. 2015;86(7):835–838.
[26] Human oral microbiom database [Internet]. Available from: www.homd.org.
[27] Whitcomb BW, Schisterman EF. Assays with lower detection limits: implications for epidemiological investigations. Paediatri Perinat Epidemiol. 2008;22(6):597–602.
[28] Croghan C, Egeghy PP. Methods of dealing with values below the limit of detection using SAS Las Vegas, NV. Available from: https://analytics.ncsu.edu/sesug/2003/SD08-Croghan.pdf

[29] Kufareva I, Salanga CL, Handel TM. Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol Cell Biol. 2015;93(4):372–383.

[30] Niwa A, Osuka K, Nakura T, et al. Interleukin-6, MCP-1, IP-10, and MIG are sequentially expressed in cerebrospinal fluid after subarachnoid hemorrhage. J Neuroinflammation. 2016;13(1):217.

[31] Lee E, Yang YH, Ho YP, et al. Potential role of vascular endothelial growth factor, interleukin-8 and monocyte chemoattractant protein-1 in periodontal diseases. Kaohsiung J Med Sci. 2003;19(8):406–415.

[32] Park OJ, Cho MK, Yun CH, et al. Lipopolysaccharide of Aggregatibacter Actinomycetemcomitans induces the expression of chemokines MCP-1, MIP-1alpha, and IP-10 via similar but distinct signaling pathways in murine macrophages. Immunobiology. 2015;220(9):1067–1074.

[33] Peyyala R, Kirakodu SS, Novak KF, et al. Oral microbial biofilm stimulation of epithelial cell responses. Cytokine. 2012;58(1):65–72.

[34] Damgaard C, Kantarci A, Holmstrup P, et al. Porphyromonas Gingivalis-induced production of reactive oxygen species, tumor necrosis factor-alpha, interleukin-6, CXCL8 and CCL2 by neutrophils from localized aggressive periodontitis and healthy donors: modulating actions of red blood cells and resolin El. J Periodontal Res. 2017;52(2):246–254.

[35] Marchesan J, Jiao Y, Schaff RA, et al. TLR4, NOD1 and NOD2 mediate immune recognition of putative newly identified periodontal pathogens. Mol Oral Microbiol. 2016;31(3):243–258.

[36] Miller CS, Foley JD, Bailey AL, et al. Current developments in salivary diagnostics. Biomark Med. 2010;4(1):171–189.

[37] Golatowski C, Salazar MG, Dhople VM, et al. Comparative evaluation of saliva collection methods for proteome analysis. Clin Chim Acta. 2013;419:42–46.

[38] Topkas E, Keith P, Dimeski G, et al. Evaluation of saliva collection devices for the analysis of proteins. Clin Chim Acta. 2012;413(13–14):1066–1070.

[39] Belstrom D, Holmstrup P, Bardow A, Kokaras A, Fiehn NE, Paster BJ. Comparative analysis of bacterial profiles in unstimulated and stimulated saliva samples. J Oral Microbiol. 2016;8:30112.

[40] Damgaard C, Holmstrup P, Van Dyke TE, et al. The complement system and its role in the pathogenesis of periodontitis: current concepts. J Periodontal Res. 2015;50(3):283–293.